Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

Phase 3

Completed

Conditions: Back Pain Lower Back Chronic

Interventions: Drug: Hydrocodone bitartrate
Drug: Placebo

Registration Number: NCT01081912

Lead Sponsor: Zogenix, Inc.

Brief Summary: The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.

Detailed Description: A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain. Subjects will go through an open-label conversion and titration phase followed by a randomized double-blind treatment phase of Hydrocodone (HC)-Controlled-Release (CR) vs. Placebo. The trial will consist of a Screening Phase (up to 14 days), an open-label Conversion and Titration Phase (up to 6 weeks), a 12-week placebo-controlled Treatment Phase, and a 2-week Follow-Up Phone Call

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 510

Inclusion Criteria

Subjects must have a clinical diagnosis of moderate to severe chronic lower back pain (CLBP)
Subjects must be classified as non-neuropathic, neuropathic, or symptomatic for more than 6 months after lower back pain (LBP) surgery
Subjects must in the Investigator's opinion qualify for around-the-clock opioid therapy for treatment of their chronic lower back pain (CLBP).
Subjects must have been taking opioids for at least 5 days/week for the past 4weeks
Subjects must have an average Clinic Pain Score of ≥ 4 on the 11-point (0-10) numeric rating scale (NRS) as an average for the last 24 hours of Screening
Subjects, in the opinion of the Investigator, must be considered to be in generally good health other then CLBP at Screening
Female subjects of childbearing potential must have a negative urine pregnancy test at the Screening Visit, and must consent to use a medically-acceptable method of contraception throughout the entire study period.
Subjects must voluntarily provide written informed consent.

Exclusion Criteria

Any clinically significant condition that would, in the opinion of the Investigator, preclude study participation or interfere with the assessment of pain and other symptoms of CLBP or increase the risk of opioid-related adverse events
A medical condition that, in the opinion of the Investigator, would compromise the subject's ability to swallow, absorb, metabolize, or excrete the study drug
A surgical procedure for back pain within 6 months
A nerve or plexus block, including epidural steroid injections or facet blocks
A history of chemotherapy or confirmed malignancy within past 2 years
Any other chronic pain condition other than CLBP that, in the Investigator's opinion, would interfere with the assessment of LBP e.g. fibromyalgia, osteoarthritis, rheumatoid arthritis, migraine headaches requiring opioid treatment
Uncontrolled blood pressure, i.e., subject has a sitting systolic blood pressure >180 mmHg or <90 mmHg, and/or a sitting diastolic blood pressure >120 mmHg or <50 mmHg at Screening
A Body Mass Index (BMI) >45 kg/m2
A Hospital Anxiety and Depression Scale (HADS) Index score of >12 in either depression or anxiety subscales or an established history of major depressive disorder that is poorly controlled with medication
A clinically significant abnormality in clinical chemistry, hematology or urinalysis

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Hydrocodone Bitartrate Capsules	Hydrocodone bitartrate	Hydrocodone Bitartrate Controlled-Release Capsules
Placebo comparator	Placebo	-

Primary Outcome Measures

Name	Time	Method
Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).	Baseline to Day 85 (Treatment Phase)	Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome.

Secondary Outcome Measures

Name	Time	Method
Mean Change of the Clinic NRS Pain Intensity	Baseline to Day 85 visit	The change in pain intensity as measured in the clinic by a 0-10 Numeric Rating Scale (NRS)

Trial Locations

Locations (49): Advanced Clinical Research Institute
🇺🇸
Anaheim, California, United States
Perimeter Institute for Clinical Research, Inc.
🇺🇸
Atlanta, Georgia, United States
Georgia Institute for Clinical Research, LLC
🇺🇸
Marietta, Georgia, United States
Suburban Clinical Research
🇺🇸
Chicago, Illinois, United States
Research West, LLC
🇺🇸
Kalispell, Montana, United States
Prestige Clinical Research
🇺🇸
Franklin, Ohio, United States
Advanced Research Institute
🇺🇸
Ogden, Utah, United States
Office of Danka Michaels, MD
🇺🇸
Las Vegas, Nevada, United States
IVA Research
🇺🇸
Cincinnati, Ohio, United States
Pacific Coast Pain Management Center
🇺🇸
Laguna Hills, California, United States
Stamford Therapeutics Consortium
🇺🇸
Stamford, Connecticut, United States
Destiny Clinical Research, LLC
🇺🇸
Evansville, Indiana, United States
Integrated Clinical Trials Services, Inc.
🇺🇸
West Des Moines, Iowa, United States
Northwest Clinical Research Center
🇺🇸
Bellevue, Washington, United States
Arizona Research Center
🇺🇸
Phoenix, Arizona, United States
Innovative Clinical Trials
🇺🇸
San Antonio, Texas, United States
Neuropsychiatric Research Center
🇺🇸
Oklahoma City, Oklahoma, United States
Feasterville Family Health Care Center
🇺🇸
Feasterville, Pennsylvania, United States
Five Towns Neuroscience Research
🇺🇸
Cedarhurst, New York, United States
New England Center for Clinical Research
🇺🇸
Cranston, Rhode Island, United States
Health Concepts
🇺🇸
Rapid City, South Dakota, United States
Clopton Clinic
🇺🇸
Jonesboro, Arkansas, United States
Neuro-Pain Medical Center, Inc.
🇺🇸
Fresno, California, United States
Clinicos, LLC
🇺🇸
Colorado Springs, Colorado, United States
Interwest Rehabilitation, LLC
🇺🇸
Littleton, Colorado, United States
Florida Institute of Medical Research
🇺🇸
Jacksonville, Florida, United States
Gold Coast Research
🇺🇸
Plantation, Florida, United States
Clinical Research of West Florida, Inc.
🇺🇸
Tampa, Florida, United States
Peninsula Research, Inc.
🇺🇸
Ormond Beach, Florida, United States
Georgia Clinical Research
🇺🇸
Snellville, Georgia, United States
River Birch Research Alliance, LLC
🇺🇸
Blue Ridge, Georgia, United States
Cotton O'Neil Clinical Research Center
🇺🇸
Topeka, Kansas, United States
International Clinical Research Institute
🇺🇸
Leawood, Kansas, United States
Clinical Trials Technology, Inc
🇺🇸
Prairie Village, Kansas, United States
Clinical Trials Management
🇺🇸
Metairie, Louisiana, United States
River Cities Clinical Research Center
🇺🇸
Shreveport, Louisiana, United States
NECCR Internal Medicine & Cardiology Associates, LLC
🇺🇸
Fall River, Massachusetts, United States
Best Clinical Trials, LLC
🇺🇸
New Orleans, Louisiana, United States
Center for Clinical Trials
🇺🇸
Biloxi, Mississippi, United States
South Jersey Medical Associates
🇺🇸
Blackwood, New Jersey, United States
CRI Worldwide, LLC
🇺🇸
Willingboro, New Jersey, United States
Upstate Clinical Research Associates
🇺🇸
Williamsville, New York, United States
Center for Clinical Research LLC
🇺🇸
Winston-Salem, North Carolina, United States
Brandywine Clinical Research
🇺🇸
Downingtown, Pennsylvania, United States
Integrity Clinical Research, LLC
🇺🇸
Milan, Tennessee, United States
InSite Clinical Research
🇺🇸
DeSoto, Texas, United States
Clinical Trial Network
🇺🇸
Spring, Texas, United States
Invisions Consultants, LLC
🇺🇸
San Antonio, Texas, United States
Hypothe Test, LLC
🇺🇸
Roanoke, Virginia, United States

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts